Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sandoz International GmbH

Division of Novartis AG
www.sandoz.com

Latest From Sandoz International GmbH

Who’s Hired? Stenico Takes Lead At Sandoz Germany

Sandoz has named Peter Stenico as permanent country head for its German operations. At the same time, Stada has appointed a trio of executives to key roles in Germany, Hovione has announced a new COO, Hikma and Orion have seen board changes and Sanofi’s biosimilars head in China has left the position for a new role.

Appointments Germany

Market Brief: Sales Of Patches To Treat Neurological Disorders Will See Fastest Growth In Global Transdermal Patch Market

The overall transdermal patch market is expected to grow at a CAGR of 2.4% by 2024. Patches to treat neurological disorders will see the fastest growth while pain-management patches will see the most sales.

Market Intelligence Innovation

String Of Positives Lifts Lupin's Outlook

Tentative FDA approval for Lupin’s arformoterol tartrate inhalation solution and a potential European nod for etanercept are seen aiding the company’s prospects in FY2021. Besides, success in a Phase III trial for secnidazole to treat trichomoniasis bodes well, though manufacturing clearances and continuity will also be closely watched.

Manufacturing Policy & Regulation

Sandoz Matches Teva On US Rifaximin Launch Date

Sandoz has joined a fellow major generics player, Teva’s Actavis, in settling itself out of litigation with Bausch Health over Xifaxan 550mg tablets in the US. The two settlement agreements contain key similarities and differences.

Intellectual Property Legal Issues
See All

Company Information

UsernamePublicRestriction

Register